Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603882's ROE % is ranked worse than 51.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.32
vs SHSE:603882: -1.53
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Guangzhou Kingmed Diagnostics Group Co ROE % Related Terms
Guangzhou Kingmed Diagnostics Group Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co ROE % Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Kingmed Diagnostics Group Co ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's ROE % distribution charts can be found below:
* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a ROE % of 2.62% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. This is 83% below median its historical median of 15.10. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #103 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 51.5%.
Is Guangzhou Kingmed Diagnostics Group Co's ROE % too high?
Guangzhou Kingmed Diagnostics Group Co's current ROE % of 2.62% is 83% below median its 10-year median of 15.10. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #103 out of 200 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #103 out of 200 companies for ROE %. This places Guangzhou Kingmed Diagnostics Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. Guangzhou Kingmed Diagnostics Group Co's current ROE % is 2.62%, which is 83% below median its own 10-year median of 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥27.91, compared to a current price of ¥26.71 — trading 4.3% below its estimated fair value. The current ROE % is 2.62%, which is 83% below median its 10-year median of 15.10. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current ROE % is 2.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be undervalued.
The current stock price of ¥26.71 is trading 4.3% below its estimated GF Value™ of ¥27.91.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
ROE %: 2.62% (83% below median its 10-year median of 15.10)
GF Value™: ¥27.91 vs. price of ¥26.71 (4.3% below fair value)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Kingmed Diagnostics Group Co Business Description
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
74GF Score
Get the complete analysis for SHSE:603882
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
